Consideration for immunogenicity assay development for oligonucleotide therapeutics.

Authors

Amily Fang-Ju Jou, Kelly M Hainline

Published in

Bioanalysis. Pages 1-15. Jul 23, 2026. Epub Jul 23, 2026.

Abstract

Oligonucleotide therapeutics (ONTs) represent a rapidly expanding drug modality driven by advances in chemical modification, sequence design, and delivery technologies. These innovations have improved pharmacokinetics, tissue targeting, and clinical efficacy, but they may also introduce modality-specific challenges for immunogenicity risk assessment. Although ONTs are regulated as small molecules and routine immunogenicity testing is not universally required, anti-drug antibody (ADA) responses have been reported and may impact pharmacokinetics and safety in certain contexts. Compared with protein therapeutics, regulatory guidance, and practical experience for immunogenicity assessment of ONTs remain limited. This review summarizes the diverse oligonucleotide types, chemical modifications, and carrier modalities used in approved and emerging ONTs and examines how these attributes influence immunogenic risk and ADA assay development. Key challenges include potential nonspecific protein binding, reagent generation, immunodominance of conjugated components, and the need for specialized assay formats. Building on established principles from protein biologics while recognizing their limitations for oligonucleotides, this review highlights risk-informed strategies for ADA assay design to support immunogenicity assessment as ONT platforms continue to evolve.

PMID:
42489037
Bibliographic data and abstract were imported from PubMed on 23 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.